Active, not recruitingPhase 3NCT05624554
A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)
Studying B-cell chronic lymphocytic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Merck Sharp & Dohme LLC
- Principal Investigator
- Medical DirectorMerck Sharp & Dohme LLC
- Intervention
- Nemtabrutinib(drug)
- Enrollment
- 300 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2031
Study locations (30)
- Highlands Oncology Group ( Site 5205), Springdale, Arkansas, United States
- Clermont Oncology Center ( Site 5224), Clermont, Florida, United States
- Hattiesburg Clinic Hematology/Oncology ( Site 5216), Hattiesburg, Mississippi, United States
- Medical Oncology Associates, PS ( Site 5206), Spokane, Washington, United States
- Royal Adelaide Hospital ( Site 1105), Adelaide, South Australia, Australia
- Hospital Erasto Gaertner-CEPEP - Pesquisa Clínica ( Site 1317), Curitiba, Paraná, Brazil
- Hospital Amaral Carvalho-Centro de Pesquisas ( Site 1304), Jaú, São Paulo, Brazil
- A. C. Camargo Cancer Center ( Site 1318), São Paulo, São Paulo, Brazil
- Instituto Nacional de Câncer - INCA-Divisão de Pesquisa Clínica e Desenvolvimento Tecnológico HC1 ( Site 1319), Rio de Janeiro, Brazil
- ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO-Pesquisa Clinica ( Site 1308), São Paulo, Brazil
- Hospital Paulistano-Americas Oncologia ( Site 1302), São Paulo, Brazil
- Specialized Hospital for Active Treatment of Haematology Diseases ( Site 6403), Sofia, Sofia (stolitsa), Bulgaria
- University Multiprofile Hospital for Active Treatment "Sveti Georgi" EAD ( Site 6404), Plovdiv, Bulgaria
- Medical Centre Pratia Clinic EOOD ( Site 6406), Plovdiv, Bulgaria
- UMHAT "Prof. Dr. Stoyan Kirkovich"AD-Clinical Hematology ( Site 6400), Stara Zagora, Bulgaria
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05624554 on ClinicalTrials.govOther trials for B-cell chronic lymphocytic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07194980Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaFred Hutchinson Cancer Center
- RECRUITINGEARLY PHASE1NCT07428707Immune Profiling of CLL/SLL Treated With First-Line PirtobrutinibNational Heart, Lung, and Blood Institute (NHLBI)
- RECRUITINGPHASE4NCT07218341A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaEli Lilly and Company
- RECRUITINGPHASE1NCT06859008Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin LymphomaCity of Hope Medical Center
- RECRUITINGPHASE2NCT07271667A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell MalignanciesCuris, Inc.
- RECRUITINGPHASE2NCT07014917Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLLZulfa Omer
- RECRUITINGPHASE2NCT06958705Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor MonotherapyThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPHASE1, PHASE2NCT07052695Mosunetuzumab for CLL MRD ClearanceInhye Ahn